Overview

Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Pfizer
Treatments:
Avibactam
Ceftazidime
Cilastatin
Imipenem
Criteria
Inclusion Criteria:

- Acute pyelonephritis or other complicated urinary tract infection due to gram negative
pathogens

Exclusion Criteria:

- ileal loops or vesicoureteral reflux

- complete obstruction of any portion of urinary tract, perinephric or intrarenal
abscess.

- fungal urinary tract infection

- permanent indirect catheter or nephrostomy unless removed within 48 hours of study
entry

- history hypersensitivity to study medication